


StreaMLine - an innovative platform for peptide drug discovery

Authors: Anita Wester¹, Claudia Hjerringgaard¹, Jens Christian Nielsen¹, Mads Mørup Nygaard¹, Morten Lundh¹, Stine Jørgensen¹, Lise Biehl Rudkjær¹, Louise S. Dalbøge¹, Niels Vrang¹ and Kristoffer Rigbolt^{1*}
 Gubra, Hørsholm Kongevej 11B, Hørsholm, Denmark
 *Corresponding author: Kristoffer Rigbolt, kri@gubra.dk

1 Accelerated peptide screening and drug development with streaMLine

The streaMLine platform


- + +4000 peptides/month
- + Systematic design of peptide libraries and complete exploration of sequences
- + Rapid peptide synthesis and characterization
- + High through-put screening of crude peptides in *in vitro* assays and on chemical- and physical parameters
- + Machine learning (ML) assisted analysis and optimization of key parameters in parallel



Hit to clinical candidate


- + Improve biophysical/CMC properties for clinical testing
- + Peptide screening integrated with state-of-the-art *in vivo* pharmacology facilities
- + Rapid determination of PK/PD relationships
- + Short time from initial hit to clinical drug candidate.
- + **streaMLine** based patent applications

2 The streaMLine drug development process



3 Using streaMLine to make selective amylin receptor agonists


- + **Amylin receptor agonists** reduce body weight
- + **Amylin** is notoriously known for its **fibril formation** and requires formulation at **low pH**
- + Non-fibrillating peptide **adrenomedullin** used as the template to develop amylin receptor-selective analogs
- + **StreaMLine platform** used to screen complete peptide sequence and identify key positions that accurately control amylin receptor selectivity



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
 (19) World Intellectual Property Organization
 International Bureau
 (43) International Publication Date
 31 March 2022 (31.03.2022)
 (10) International Publication Number
WO 2022/063925 A1
 WIPO PCT
 (54) Title: HAMI-52 ANALOGUES WITH IMPROVED AMYLIN RECEPTOR (HAMY3R) POTENCY

The amylin program showcase

- + **StreaMLine** based development of novel amylin analogs
- + 10 % weight loss in DIO mice
- + PK suitable for once weekly dosing
- + Formulation at neutral pH




4 One-stop shop for peptide drug discovery



Liver (NASH)



Diabetes




Kidney (CKD)



Obesity



Lungs



Intestine (IBD)



CNS



Heart (CVD)

NASH, CKD, CVD, IPF, obesity, diabetes, IBD, Parkinson, Alzheimer's disease among others...



Claudia Hjerringgaard, PhD
 Senior Scientist
 chj@gubra.dk



Anita Wester, PhD
 Research Scientist
 awe@gubra.dk

Scan the QR code and find out more →

